Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors

The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology

Research output: Contribution to journalArticle

Abstract

The publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 WHO CNS) represented a major change in the classification of brain tumors. However, many pathologists in Japan cannot diagnose astrocytic or oligodendroglial tumors according to the 2016 WHO CNS due to financial or technical problems. Therefore, the Japan Society of Brain Tumor Pathology established a committee for molecular diagnosis to facilitate the integrated diagnosis of astrocytic and oligodendroglial tumors in Japan. We created three levels of diagnoses: Level 1 was defined as simple histopathological diagnosis using hematoxylin and eosin staining and routine cell lineage-based immunostaining. Level 2 was defined as immunohistochemical diagnosis using immunohistochemical examinations using R132H mutation-specific IDH1, ATRX, and/or p53 antibodies. Level 3 was defined as molecular diagnosis, such as diagnosis based on 1p/19q status or the mutation status of the IDH1 and IDH2 genes. In principle, astrocytic and oligodendroglial tumors should be diagnosed based on the 2016 WHO CNS and/or cIMPACT-NOW criteria; however, the findings obtained through our diagnostic flowchart can be added to the histological diagnosis in parentheses. This classification system would be helpful for pathologists with limited resources.

Original languageEnglish
Pages (from-to)56-62
Number of pages7
JournalBrain tumor pathology
Volume36
Issue number2
DOIs
Publication statusPublished - 2019 Apr 25

Fingerprint

Central Nervous System Neoplasms
Neoplasms
Japan
Brain Neoplasms
Software Design
Mutation
Cell Lineage
Hematoxylin
Eosine Yellowish-(YS)
Publications
Pathology
Staining and Labeling
Antibodies
Genes
Pathologists

Keywords

  • 1p/19q-codeletion
  • Glioma
  • IDH mutation
  • WHO classification

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology (2019). Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. Brain tumor pathology, 36(2), 56-62. https://doi.org/10.1007/s10014-019-00337-y

Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. / The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology.

In: Brain tumor pathology, Vol. 36, No. 2, 25.04.2019, p. 56-62.

Research output: Contribution to journalArticle

The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology 2019, 'Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors', Brain tumor pathology, vol. 36, no. 2, pp. 56-62. https://doi.org/10.1007/s10014-019-00337-y
The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology. Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. Brain tumor pathology. 2019 Apr 25;36(2):56-62. https://doi.org/10.1007/s10014-019-00337-y
The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology. / Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. In: Brain tumor pathology. 2019 ; Vol. 36, No. 2. pp. 56-62.
@article{43c3f35ea99e40508cd47f15ed196c71,
title = "Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors",
abstract = "The publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 WHO CNS) represented a major change in the classification of brain tumors. However, many pathologists in Japan cannot diagnose astrocytic or oligodendroglial tumors according to the 2016 WHO CNS due to financial or technical problems. Therefore, the Japan Society of Brain Tumor Pathology established a committee for molecular diagnosis to facilitate the integrated diagnosis of astrocytic and oligodendroglial tumors in Japan. We created three levels of diagnoses: Level 1 was defined as simple histopathological diagnosis using hematoxylin and eosin staining and routine cell lineage-based immunostaining. Level 2 was defined as immunohistochemical diagnosis using immunohistochemical examinations using R132H mutation-specific IDH1, ATRX, and/or p53 antibodies. Level 3 was defined as molecular diagnosis, such as diagnosis based on 1p/19q status or the mutation status of the IDH1 and IDH2 genes. In principle, astrocytic and oligodendroglial tumors should be diagnosed based on the 2016 WHO CNS and/or cIMPACT-NOW criteria; however, the findings obtained through our diagnostic flowchart can be added to the histological diagnosis in parentheses. This classification system would be helpful for pathologists with limited resources.",
keywords = "1p/19q-codeletion, Glioma, IDH mutation, WHO classification",
author = "{The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology} and Yukihiko Sonoda and Hideaki Yokoo and Shinya Tanaka and Manabu Kinoshita and Mitsutoshi Nakada and Hiroshi Nishihara and Koichi Ichimura and Hidehiro Oka and Junji Shibahara and Naoya Hashimoto and Yonehiro Kenemura and Atsushi Natsume and Sumito Nobusawa and Keisuke Ueki and Takashi Komori and Makoto Shibuya and Akira Matsumura",
year = "2019",
month = "4",
day = "25",
doi = "10.1007/s10014-019-00337-y",
language = "English",
volume = "36",
pages = "56--62",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors

AU - The committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology

AU - Sonoda, Yukihiko

AU - Yokoo, Hideaki

AU - Tanaka, Shinya

AU - Kinoshita, Manabu

AU - Nakada, Mitsutoshi

AU - Nishihara, Hiroshi

AU - Ichimura, Koichi

AU - Oka, Hidehiro

AU - Shibahara, Junji

AU - Hashimoto, Naoya

AU - Kenemura, Yonehiro

AU - Natsume, Atsushi

AU - Nobusawa, Sumito

AU - Ueki, Keisuke

AU - Komori, Takashi

AU - Shibuya, Makoto

AU - Matsumura, Akira

PY - 2019/4/25

Y1 - 2019/4/25

N2 - The publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 WHO CNS) represented a major change in the classification of brain tumors. However, many pathologists in Japan cannot diagnose astrocytic or oligodendroglial tumors according to the 2016 WHO CNS due to financial or technical problems. Therefore, the Japan Society of Brain Tumor Pathology established a committee for molecular diagnosis to facilitate the integrated diagnosis of astrocytic and oligodendroglial tumors in Japan. We created three levels of diagnoses: Level 1 was defined as simple histopathological diagnosis using hematoxylin and eosin staining and routine cell lineage-based immunostaining. Level 2 was defined as immunohistochemical diagnosis using immunohistochemical examinations using R132H mutation-specific IDH1, ATRX, and/or p53 antibodies. Level 3 was defined as molecular diagnosis, such as diagnosis based on 1p/19q status or the mutation status of the IDH1 and IDH2 genes. In principle, astrocytic and oligodendroglial tumors should be diagnosed based on the 2016 WHO CNS and/or cIMPACT-NOW criteria; however, the findings obtained through our diagnostic flowchart can be added to the histological diagnosis in parentheses. This classification system would be helpful for pathologists with limited resources.

AB - The publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 WHO CNS) represented a major change in the classification of brain tumors. However, many pathologists in Japan cannot diagnose astrocytic or oligodendroglial tumors according to the 2016 WHO CNS due to financial or technical problems. Therefore, the Japan Society of Brain Tumor Pathology established a committee for molecular diagnosis to facilitate the integrated diagnosis of astrocytic and oligodendroglial tumors in Japan. We created three levels of diagnoses: Level 1 was defined as simple histopathological diagnosis using hematoxylin and eosin staining and routine cell lineage-based immunostaining. Level 2 was defined as immunohistochemical diagnosis using immunohistochemical examinations using R132H mutation-specific IDH1, ATRX, and/or p53 antibodies. Level 3 was defined as molecular diagnosis, such as diagnosis based on 1p/19q status or the mutation status of the IDH1 and IDH2 genes. In principle, astrocytic and oligodendroglial tumors should be diagnosed based on the 2016 WHO CNS and/or cIMPACT-NOW criteria; however, the findings obtained through our diagnostic flowchart can be added to the histological diagnosis in parentheses. This classification system would be helpful for pathologists with limited resources.

KW - 1p/19q-codeletion

KW - Glioma

KW - IDH mutation

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=85062694270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062694270&partnerID=8YFLogxK

U2 - 10.1007/s10014-019-00337-y

DO - 10.1007/s10014-019-00337-y

M3 - Article

VL - 36

SP - 56

EP - 62

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

IS - 2

ER -